GlobeNewsWire · JNJ · October 24, 2026

NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma

Get the app for more

Explore stock news, insights and company research.